Serum markers of cardiac fibrosis suffering from heart failure with preserved left ventricular ejection fraction upon ST-segment elevation myocardial infarction

Aim. Currently, there is no method which accurately predicts an adverse outcome of heart failure with a preserved left ventricular ejection fraction (HFpEF) upon ST-segment elevation myocardial infarction (STEMI). Here we studied the prognostic significance of procollagen type I C-terminal propeptide (PICP) and procollagen type III N-terminal propeptide (PIIINP) in patients with post-STEMI HFpEF.

Material and Methods. The study included 83 patients (60 men and 23 women) with post-STEMI HFpEF (left ventricular EF ≥ 50%) and 20 ageand gender-matched healthy controls. Serum concentrations of PICP and PIIINP were measured on the 1st day of hospitalization using enzyme-linked immunosorbent assay with the following calculation of PICP/PIIINP ratio.

Results. Serum PICP and PIIINP on the 1st day of STEMI significantly (3.4-fold) exceeded the values of the control group and were as follows: PIIINP: 26.0 (18.9; 34.9) ng/mL (р = 0.047); PICP: 609.0 (583.0; 635.0) ng/mL (р = 0.049).

Conclusion. Elevated values of procollagens indicate that cardiac fibrosis commences within the 24 hours after STEMI onset. The pivotal role of cardiac fibrosis in the formation of diastolic dysfunction suggests the usefulness of serum procollagens to predict the development of HFpEF in a long-term period upon STEMI.

1. Miklishanskaya SV, Mazur NA, Shestakova NV. Mechanisms for the formation myocardial fibrosis in norm and in certain cardiovascular diseases, how to diagnose it. Medical council. 2017;12:75-81. (In Russ). https://doi.org/10.21518/2079-701X-2017-12-75-81

2. Husain-Syed F, McCullough PA, Birk HW, Renker M, Brocca A, Seeger W, Ronco C. Cardio-Pulmonary-Renal Interactions: A Multidisciplinary Approach. J Am Coll Cardiol. 2015;65(22):2433-2448. https://doi.org/10.1016/j.jacc.2015.04.024

3. Ambale-Venkatesh B, Liu CY, Liu YC, Donekal S, Ohyama Y, Sharma RK, Wu CO, Post WS, Hundley GW, Bluemke DA, Lima JAC. Association of myocardial fibrosis and cardiovascular events: the multi-ethnic study of atherosclerosis. Eur Heart J Cardiovasc Imaging. 2019;20(2):168-176. https://doi.org/10.1093/ehjci/jey140

4. Fomin IV. Chronic heart failure in the Russian Federation: what do we know and what to do. Russian journal of cardiology. 2016;21(8):7-13. (In Russ). https://doi.org/10.15829/1560-4071-2016-8-7-13

5. Ferreira JP, Kraus S, Mitchell S, Perel P, Piñeiro D, Chioncel O, Colque R, de Boer RA, Gomez-Mesa JE, Grancelli H, Lam CSP, Martinez-Rubio A, McMurray JJV, Mebazaa A, Panjrath G, Piña IL, Sani M, Sim D, Walsh M, Yancy C, Zannad F, Sliwa K. World Heart Federation Roadmap for Heart Failure. Glob Heart. 2019;14(3):197-214. https://doi.org/10.1016/j.gheart.2019.07.004

6. Bloom MW, Greenberg B, Jaarsma T, Januzzi JL, Lam CSP, Maggioni AP, Trochu JN, Butler J. Heart failure with reduced ejection fraction. Nat Rev Dis Primers. 2017;3:17058. https://doi.org/10.1038/nrdp.2017.58

7. Solomakhina NI, Belenkov YuN, Varshavskiy VA. Fibroz miokarda pri sistolicheskoy i diastolicheskoy khronicheskoy serdechnoy nedostatochnosti. Moscow : M.: Medpraktika-m, 2014. (In Russ).

8. Gandhi PU, Gaggin HK, Redfield MM, Chen HH, Stevens SR, Anstrom KJ, Semigran MJ, Liu P, Januzzi JL Jr. Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial. JACC Heart Fail. 2016;4(11):860- 869. https://doi.org/10.1016/j.jchf.2016.08.002

9. López B, González A, Querejeta R, Zubillaga E, Larman M, Díez J. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. Eur J Heart Fail. 2015;17(4):385-392. https://doi.org/10.1002/ejhf.246

10. Vainio LE, Szabó Z, Lin R, Ulvila J, Yrjölä R, Alakoski T, Piuhola J, Koch WJ, Ruskoaho H, Fouse SD, Seeley TW, Gao E, Signore P, Lipson KE, Magga J, Kerkelä R. Connective Tissue Growth Factor Inhibition Enhances Cardiac Repair and Limits Fibrosis After Myocardial Infarction. JACC Basic Transl Sci. 2019;4(1):83-94. https://doi.org/10.1016/j.jacbts.2018.10.007

11. Mareev VYu, Ageev FT, Arutyunov GP, Koroteev AV, Mareev YuV, Ovchinnikov AG, Belenkov YuN, Vasyuk YuA, Galyavich AS, Garganeeva AA, Gilyarevsky SR, Glezer MG, Koziolova NA, Kots YaI, Lopatin YuM, Martynov AI, Moiseev VS, Revishvili ASh, Sitnikova MYu, Skibitsky VV, Sokolov EI, Storozhakov GI, Fomin IV, Chesnikova AI, Shlyakhto EV, Akchurin RS, Aronov DM, Arkhipov MV, Bart BYa, Belousov YuB, Boitsov SA, Gendlin GE, Golikov AP, Golitsyn SP, Gurevich MA, Danielyan MO, Dovgalevsky PYa, Zadionchenko VS, Karpov RS, Karpov YuA, Kobalava ZhD, Kuznetsov VA, Lazebnik LB, Nasonov EL, Nedogoda SV, Nikitin YuP, Oganov RG, Panchenko EP, Perepech NB, Podzolkov VI, Pozdnyakov YuA, Rakov AL, Ruda MYa, Rylova AK, Simonenko VB, Sidorenko BA, Staroverov II, Sulimov VA, Tarlovskaya EI, Tereshchenko SN, Fomina IG, Chazova IE, Drapkina OM. Sehf, rsc and rsmsim national guidelines on chf diagnostics and treatment (fourth revision). approved at the sehf congress on december 7, 2012, at the sehf board of directors meeting on march 31, 2013, and at the rsc congress on september 25, 2013. Russian heart failure journal. 2013;14(7(81):379-472. (In Russ).

12. Ruda MYa, Averkov OV, Golitsyn SP, Graciansky NA, Komarov AL, Panchenko EP, Pevzner DV, Yavelov IS. Diagnosis and management of st-segment elevation myocardial infarction. Russian cardiology bulletin. 2014;9(4):3-60. (In Russ).

13. Schüttler D, Clauss S, Weckbach LT, Brunner S. Molecular Mechanisms of Cardiac Remodeling and Regeneration in Physical Exercise. Cells. 2019;8(10):1128. https://doi.org/10.3390/cells8101128

14. Drapkina OM, Zyatenkova EV. Evaluation of cardiovascular remodeling and epicardial fat thickness in patients with chronic heart failure and metabolic syndrome. Therapeutic archive. 2016;88(2):64-70. (In Russ).

15. Frangogiannis NG. Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Aspects Med. 2019;65:70-99. https://doi.org/10.1016/j.mam.2018.07.001

16. Klimchuk DO, Polunina OS, Sevostyanova IV, Voronina LP, Polunina EA, Prokofeva TV. Assessment of C-terminal telopeptide type I collagen in patients with chronic heart failure on the background of atrial fibrillation and post-infarction cardiosclerosis. Kuban Scientific Medical Bulletin. 2016;1(156):74-76. (In Russ).

17. Govorin AV, Ratsina EV, Fetisova NV, Sokolova NA. Blood level of collagen biomarkers and sulfated glycosaminoglycans in acute transmural myocardial infarction. Russian Journal of Cardiology. 2016;(3):75-79. (In Russ). https://doi.org/10.15829/1560-4071-2016-3-75-79

18. Sumin AN, Osokina AV, Shcheglova AV, Frolova SA, Barbarash OL. Assessment of cardio-ankle vascular index in patients with coronary artery disease with a different type of diastolic dysfunction of the left ventricle. Kompleksnye problemy serdechno-sosudistykh zabolevaniy. 2016;5(2):51-58. (In Russ). https://doi.org/10.17802/2306-1278-2016-2-51-58

19. Drapkina OM, Ziatenkova EV. Fibrosis markers in metabolic syndrome. RMZh. Meditsinskoe obozrenie. 2016;(26):1727-1731. (In Russ).

20. Mareev VYU, Fomin IV, Ageev FT, Begrambekova YUL, Vasyuk YUA, Garganeeva AA, Gendlin GE, Glezer MG, Gautier SV, Dovzhenko TV, Kobalava ZHD, Koziolova NA, Koroteev AV, Mareev YUV, Ovchinnikov AG, Perepech NB, Tarlovskaya EI, Chesnikova AI, Shevchenko AO, Arutyunov GP, Belenkov YUN, Galyavich AS, Gilyarevsky SR, Drapkina OM, Duplyakov DV, Lopatin YUM, Sitnikova MYU, Skibitsky VV, Shlyakhto EV. Russian heart failure society, russian society of cardiology. russian scientific medical society of internal medicine guidelines for heart failure: chronic (chf) and acute decompensated (adhf). Diagnosis, prevention and treatment. Cardiology. 2018;58(S6): 8-158 (In Russ). https://doi.org/10.18087/cardio.2475